Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.
White
Deborah L
DL
Saunders
Verity A
VA
Quinn
Steven R
SR
Manley
Paul W
PW
Hughes
Timothy P
TP
D000818:Animals; D000970:Antineoplastic Agents / Q000819:agonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D002460:Cell Line; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008954:Models, Biological; D019000:Phosphotyrosine / Q000378:metabolism; D010879:Piperazines / Q000819:agonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D011743:Pyrimidines / Q000819:agonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D019000:Phosphotyrosine; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib